Status: Ongoing, but not recruiting
ClinicalTrials.gov Identifier: NCT02462928
150998-005: A Phase III, Multi-Center, randomized, double-masked, parallel group to assess the Safety and Efficacy of Abicipar compared to Ranibizumab in patients with Neovascular Age-Related Macular Degeneration.
Condition: Macular Degeneration
Study Type: Interventional
Duration: 104 weeks
For additional information on this study, please click hereBack to Clinical Research